Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 938 000 KRW -1.16% Market Closed
Market Cap: 66.8T KRW
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Net Margin
Samsung Biologics Co Ltd

24.1%
Current
25%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.1%
=
Net Income
1.1T
/
Revenue
4.4T

Net Margin Across Competitors

Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 200.9B USD
Net Margin
14%
Country US
Market Cap 165.5B USD
Net Margin
18%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.4B USD
Net Margin
20%
Country US
Market Cap 36.2B USD
Net Margin
9%
Country US
Market Cap 26.8B USD
Net Margin
21%
Country US
Market Cap 23.9B USD
Net Margin
17%
Country CN
Market Cap 164.4B CNY
Net Margin
21%
Country US
Market Cap 22B USD
Net Margin
21%
No Stocks Found

Samsung Biologics Co Ltd
Glance View

Market Cap
66.8T KRW
Industry
Life Sciences Tools & Services

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

Intrinsic Value
491 090.73 KRW
Overvaluation 48%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.1%
=
Net Income
1.1T
/
Revenue
4.4T
What is the Net Margin of Samsung Biologics Co Ltd?

Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Net Margin of 24.1%.